A Promising Update for Eye Health Roche has recently unveiled encouraging one-year Phase III data regarding the efficacy and safety of vamikibart (RG6116) for patients suffering from uveitic macular edema (UME). This development marks a significant milestone in ophthalmology, offering a potential new therapeutic avenue for those facing vision-threatening complications from non-infectious uveitis. Understanding the…